Related Experiment Video
Updated: Jul 12, 2025

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
Brusatol enhances MEF2A expression to inhibit RCC progression through the Wnt signalling pathway in renal cell
1Department of Urology, General Hospital of the Central Theater Command, Wuhan, China.
Abstract:
Renal cell carcinoma (RCC) is the most aggressive subtype of kidney tumour with a poor prognosis and an increasing incidence rate worldwide. Brusatol, an essential active ingredient derived from Brucea javanica, exhibits potent antitumour properties. Our study aims to explore a novel treatment strategy for RCC patients. We predicted 37 molecular targets of brusatol based on the structure of brusatol, and MEF2A (Myocyte Enhancer Factor 2A) was selected as our object through bioinformatic analyses. We employed various experimental techniques, including RT-PCR, western blot, CCK8, colony formation, immunofluorescence, wound healing, flow cytometry, Transwell assays and xenograft mouse models, to investigate the impact of MEF2A on RCC. MEF2A expression was found to be reduced in patients with RCC, indicating a close correlation with MEF2A deubiquitylation. Additionally, the protective effects of brusatol on MEF2A were observed. The overexpression of MEF2A inhibits RCC cell proliferation, invasion and migration. In xenograft mice, MEF2A overexpression in RCC cells led to reduced tumour size compared to the control group. The underlying mechanism involves the inhibition of RCC cell proliferation, invasion, migration and epithelial-mesenchymal transition (EMT) through the modulation of Wnt/β-catenin signalling. Altogether, we found that MEF2A overexpression inhibits RCC progression by Wnt/β-catenin signalling, providing novel insight into diagnosis, treatment and prognosis for RCC patients.
Insights
Myocyte enhancer factor 2A (MEF2A) overexpression inhibits renal cell carcinoma (RCC) progression. This study reveals MEF2A
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Renal cell carcinoma (RCC) is an aggressive kidney tumor with increasing incidence and poor prognosis.
- Brusatol, derived from Brucea javanica, shows potent antitumour properties.
- Identifying novel therapeutic targets for RCC is crucial.
Purpose of the Study:
- To investigate the role of Myocyte Enhancer Factor 2A (MEF2A) in renal cell carcinoma (RCC).
- To explore brusatol's protective effects on MEF2A in RCC.
- To elucidate the underlying molecular mechanisms of MEF2A in inhibiting RCC progression.
Main Methods:
- Bioinformatic analysis to identify brusatol targets, selecting MEF2A.
- In vitro assays (RT-PCR, Western blot, CCK8, colony formation, immunofluorescence, wound healing, flow cytometry, Transwell) and in vivo xenograft mouse models.
- Investigation of MEF2A expression, deubiquitylation, and its impact on Wnt/β-catenin signaling.
Main Results:
- MEF2A expression is reduced in RCC patients and correlates with deubiquitylation.
- Brusatol demonstrated protective effects on MEF2A.
- MEF2A overexpression inhibited RCC cell proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT), reducing tumor size in mice via Wnt/β-catenin signaling modulation.
Conclusions:
- MEF2A functions as a tumor suppressor in RCC.
- MEF2A overexpression inhibits RCC progression through the Wnt/β-catenin signaling pathway.
- MEF2A represents a potential diagnostic marker and therapeutic target for RCC.
Related Concept Videos
Master Transcription Regulators
Canonical Wnt Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Non-Canonical Wnt Signaling Pathways
Abnormal Proliferation
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

